Defibrillators to be located in middle of TransPennine Express trains
Defibrillators are being installed across a fleet of TransPennine Express (TPE) trains over the next two months.
The train operator, which serves York, plans to equip 51 of its 185 trains with the life-saving units by the end of March.
The defibrillators, which can be used by both staff and passengers if somebody goes into cardiac arrest, will be fitted by Siemens Mobility and will be located in an emergency equipment cupboard in the middle of the train.
Bushra Khan, head of engineering at TPE, said: "Our defibrillators are a huge benefit to both our customers and the communities we serve.
"This rollout will ensure that people travelling on our services will feel safe and confident that defibrillators are available to help in the event of an emergency, potentially saving lives."
The defibrillators come with step-by-step, spoken word instructions built-in, to guide users on how to use them.
Computers inside the defibrillators analyse heart rhythms to determine if an electric shock is needed; electrodes then automatically deliver the shock if required.
Sambit Banerjee, joint CEO of Siemens Mobility UK & Ireland, said: "It's great to see the collaborative work with TPE to install life-saving defibrillators on our Class 185 trains."
The defibrillators were purchased from the British Heart Foundation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
02-04-2025
- Associated Press
Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine
Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer's, the possibilities are vast. While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments. The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine. Now, let's take a closer look at a few stocks making waves in this sector. ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA's recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector. One of the company's standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country. ADIA's medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient's blood, is being used to treat a variety of conditions, including Alzheimer's disease. This is a major move in a rapidly growing field. According to ADIA's CEO, Larry Powalisz, 'Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.' This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases. Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, 'We're crafting a movement for reliability and excellence.' The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry. On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company's treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA's international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow. Lastly, ADIA's asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA's stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions. ADIA Nutrition's combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve. Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company's approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective. One of the most promising candidates in Fate's pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn't require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate's President of Research and Development, expressed his excitement over the results, saying, 'We are pleased with the early clinical data, which continues to support the potential for disease transformation.' In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly. Fate's pipeline doesn't stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers. On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company's strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential. With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead. Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company's therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others. Mesoblast's FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil. The company is also working on expanding Ryoncil's applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases. In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications. Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast's CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, 'Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy.' Overall, Mesoblast's strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally. CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company's flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024. Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a 'milestone-rich year' with major clinical updates expected across the company's pipeline. While CASGEVY's commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression. CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex's commercial expertise as they roll out the therapy globally. Disclaimers: RazorPitch Inc. 'RazorPitch' is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact City: NAPLES State: Florida Country: United States
Yahoo
25-03-2025
- Yahoo
Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage. To view an enhanced version of this graphic, please visit: Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States. "We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach." Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity. While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders. For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit or contact ceo@ About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
18-03-2025
- Associated Press
Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom
The stem cell and regenerative medicine sector is experiencing a wave of innovation, driven by cutting-edge technologies and an expanding range of applications across healthcare, biotechnology, and even food security. With the potential to revolutionize treatments for conditions like Alzheimer's, autoimmune disorders, and cancer, stem cell therapies are unlocking new possibilities for regenerative medicine. Advances in iPSC (induced pluripotent stem cells), umbilical cord stem cells, and 3D cell-based platforms are fueling this growth, while increasing demand for affordable and accessible treatments is pushing the market forward. Valued at over $15 billion, the global stem cell market is projected to reach USD 48.83 billion by 2034, registering a CAGR of 11.3% from 2024 to 2034. This remarkable growth reflects the sector's potential as breakthroughs in research translate into real-world applications. From therapies that harness the body's own healing mechanisms to scalable solutions addressing global challenges, the opportunities for innovation and investment are immense. Now, let's explore four stocks making waves in this dynamic and transformative sector. Adia Nutrition Inc. (OTC: ADIA) is making significant strides in the growing global stem cell market with its innovative approach to regenerative medicine. The company operates two key divisions: Adia Labs, which provides premium organic supplements, and Adia Med, its medical division specializing in advanced stem cell therapies such as Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT). By focusing on affordability and accessibility, Adia Nutrition is positioning itself as a leader in the rapidly expanding field of regenerative medicine. On March 17, 2025, Adia Med announced that all future full-service clinic locations across the U.S. will offer Therapeutic Plasma Exchange (TPE), a cutting-edge procedure that removes harmful substances from the bloodstream. Already available at the company's Winter Park, Florida clinic, TPE has shown promise in treating Alzheimer's disease, autoimmune disorders, and even complications from COVID-19. The treatment utilizes the same advanced apheresis machines used in Hematopoietic Stem Cell Transplantation (HSCT), reinforcing Adia Med's commitment to leveraging state-of-the-art medical technology. Earlier in March, Adia Labs reached a major milestone with the FDA registration of Adia Vita, its premier stem cell product. Each unit contains 100 million viable cells and 3 trillion exosomes, offering a powerful and cost-effective solution in regenerative medicine. This FDA registration enables Adia Labs to distribute Adia Vita nationwide, expanding access to cutting-edge stem cell therapies for doctors and clinics across the country. With traditional stem cell treatments often costing between $15,000 and $35,000 per procedure, Adia Med stands out by offering high-quality therapies at more affordable rates, fueling rapid client growth. Adia Nutrition's growth trajectory in 2025 has been marked by several key corporate advancements. In February, the company took steps to strengthen its financial and operational foundation by retiring 25 million undocumented shares, successfully removing its shell risk designation, and launching Adia Labs LLC. These strategic moves not only reinforce investor confidence but also set the stage for an OTCQB uplisting, which will enhance the company's market visibility and liquidity. To accelerate its expansion, Adia Med is forming partnerships with elite Medical Spas, establishing satellite locations that provide a scalable and low-risk model for nationwide growth. With over 4.5 million Florida residents aged 65 and older, Adia Med is uniquely positioned to address a significant demand for age-related treatments, particularly for conditions like Alzheimer's and autoimmune disorders. With the expansion of TPE, the nationwide rollout of Adia Vita, and the impending OTCQB uplisting, ADIA is entering a phase of rapid growth. As Adia Nutrition Inc. (OTC: ADIA) continues to scale operations and push the boundaries of regenerative medicine, it is well-positioned to deliver innovative healthcare solutions while generating value for investors, making it a stock to keep an eye on. Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company specializing in iPSC-derived cellular immunotherapies. The company's proprietary platform creates engineered iPSC lines for off-the-shelf T-cell and NK-cell products, targeting diseases in autoimmunity and oncology. Fate's lead program, FT819, is an iPSC-derived CAR T-cell therapy for systemic lupus erythematosus (SLE), now in Phase 1 trials. Recent dose-expansion data from SLE patients show promising results, including no significant toxicities and one patient achieving clinical remission. The company is also exploring FT819's potential in other autoimmune diseases. Fate's FT825 CAR T-cell therapy targets solid tumors and is being tested in combination with monoclonal antibodies in collaboration with Ono Pharmaceutical. Early data show favorable safety and cellular activity. The company's FT522 CAR NK cell therapy for B-cell lymphoma is progressing, with the added advantage of not requiring conditioning chemotherapy, thanks to its Alloimmune Defense Receptor (ADR) technology. FT522 is also being evaluated for autoimmune conditions. With $307 million in cash, Fate is well-funded through 2026, allowing it to advance these promising therapies. As the company pushes forward in clinical trials, Fate Therapeutics stands out in the growing field of off-the-shelf stem cell-based treatments with growth potential. Ginkgo Bioworks (NYSE: DNA) is a leading cell programming platform, offering end-to-end solutions across industries like food, agriculture, pharmaceuticals, and biosecurity. Their biosecurity division focuses on next-generation infrastructure to help detect and respond to biological threats. In Q4 2024, Ginkgo reported total revenue of $44 million, up 26% from the previous year. This growth was driven by a 29% increase in cell engineering revenue, which reached $35 million. Biosecurity revenue grew modestly to $9 million, reflecting an evolving business model. For the full year, Ginkgo posted $227 million in revenue, down 10% due to the transition in their biosecurity business and a shift in focus toward larger customers in cell engineering. Despite the dip in overall revenue, Ginkgo reduced its GAAP net loss significantly, reporting $547 million, compared to $893 million in 2023. Their adjusted EBITDA loss also improved, dropping from $365 million to $293 million. The company ended 2024 with $562 million in cash, positioning them well to execute their strategy. Strategically, Ginkgo has made notable strides in cell engineering, with 31 new customer programs added in Q4 2024. They also signed a key contract with a top biopharmaceutical company for their antibody developability product. Their Ginkgcellutomation division was selected for a $9.4 million project with Carnegie Mellon to develop bioelectronic devices. Looking ahead, Ginkgo aims to reach adjusted EBITDA breakeven by 2026 and has targeted $250 million in cost reductions by Q3 2025. For 2025, Ginkgo projects $160-$180 million in total revenue, with $110-$130 million expected from Cell Engineering and at least $50 million from Biosecurity. With a strong cash position and clear cost-cutting initiatives, Ginkgo could be poised for sustainable growth, particularly in its core cell engineering and biosecurity sectors. Pluri Inc. (Nasdaq: PLUR) stands out in the crowded biotech and stem cell sectors due to its innovative approach to leveraging its proprietary 3D cell-based technology platform. Unlike many other companies that primarily focus on regenerative medicine, Pluri is expanding its impact into areas like foodtech and agtech, making it a versatile and dynamic player. Its cutting-edge technology addresses a wide range of global challenges, from medical advancements to food security and sustainability. By offering scalable, cost-effective, and consistent cell production, Pluri is positioning itself as a leader in creating next-generation solutions for some of the world's most pressing issues. What really sets Pluri apart is its unique capability to apply its cell-based technology across diverse industries. For example, the company is taking a significant leap into the food industry by partnering with Kokomodo Ltd., an AgTech company focused on cultivated cacao. This move aligns Pluri with the rapidly growing demand for sustainable food production and plant-based alternatives. By acquiring a 71% stake in Kokomodo, Pluri is expanding its reach into the cultivated cacao market, which is expected to grow significantly in the coming years. The deal not only positions Pluri to tap into the billion-dollar cacao market but also showcases its ability to diversify into unconventional applications for cell-based technologies. Moreover, Pluri is expanding its role in global crisis response through its collaboration with Hemafund Ltd. to address the potential need for countermeasures against radiation exposure in Ukraine. The collaboration aims to produce and stockpile PLX-R18, a cell therapy designed to treat Hematopoietic Acute Radiation Syndrome (H-ARS), which could be crucial in the event of nuclear threats. This kind of forward-thinking approach, combining biotech innovation with real-world emergency preparedness, shows Pluri's broader vision for applying its technology to urgent global health needs, making it more than just another biotech company in a competitive market. The company's recent $6.5 million investment and acquisition announcements reinforce its commitment to growth and innovation. These moves position Pluri not only as a major player in regenerative medicine and cell-based therapies but as a company with the flexibility and vision to push the boundaries of what biotech can achieve across different sectors. By aligning itself with other industries, such as food production and emergency preparedness, Pluri has shown that it is not just riding trends in the biotech space, but rather, shaping the future of multiple industries with its versatile, scalable technologies. Disclaimers: RazorPitch Inc. 'RazorPitch' is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. City: NAPLES State: Florida Country: United States
